40258-80-8

Usage

Ester

Derived from pivalic acid and 1-chloroethanol Indicates the functional group present in the compound, formed by the reaction between an acid and an alcohol.

Physical state

Colorless liquid Describes the appearance and state of the compound at room temperature.

Odor

Fruity Describes the smell of the compound, reminiscent of fruit.

Applications

a. Chemical intermediate Used in the production of pharmaceuticals and pesticides.
b. Solvent Utilized as a dissolving agent for various substances.
c. Raw material in organic synthesis Serves as a starting material for the synthesis of other organic compounds.

Hazardous substance

Potential health and safety risks Highlights the need for careful handling due to its potential to cause harm.

Skin and eye irritation

Can cause irritation Points out the compound's potential to cause discomfort or damage to the skin and eyes upon contact.

Flammable

Susceptible to ignition and combustion Emphasizes the need for caution when handling the compound due to its propensity to catch fire and burn.

InChI:InChI=1/C7H13ClO2/c1-5(8)10-6(9)7(2,3)4/h5H,1-4H3

Upstream product

• 3282-30-2 pivaloyl chloride 
• 75-07-0 acetaldehyde 
• 75-98-9 Trimethylacetic acid 
• 123-63-7 paracetaldehyde 
• 630-19-3 pivalaldehyde 
• 593-96-4 1-bromo-1-chloroethane 
• 1184-88-9 sodium pivalate 
• 122364-93-6 1-(phenylthio)ethyl pivalate 

Downstream Products

• 79116-62-4 1-(2,2-dimethyl-1-oxopropoxy)ethyl L-N-(phenylmethoxycarbonyl) tyrosinate 
• 81660-38-0 α-methyldopa pivaloylethyl ester 
• 102108-09-8 3-(3,4-Dihydroxy-phenyl)-2-[1-(2,2-dimethyl-propionyloxy)-ethylamino]-2-methyl-propionic acid 1-(2,2-dimethyl-propionyloxy)-ethyl ester 
• 581106-32-3 [3-[acetyl(phenylmethoxy)amino]propyl]-phosphonic acid bis[1-(2,2-dimethylpropionyloxy)ethyl] ester 
• 865622-29-3 [3-[acetyl(phenylmethoxy)amino]propyl]-phosphonic acid benzyl-[1-(2,2-dimethylpropionyloxy)ethyl] ester 
• 1402832-60-3 C₃₄H₄₀N₄O₆ 
• 1402832-62-5 C₃₄H₄₀N₄O₆ 

Relevant academic research and scientific papers

N-substituted imidazole carboxylate compound, preparation method and medical uses thereof

The present invention relates to a compound represented by a general formula (I) or a stereoisomer, a solvate, a pharmaceutically acceptable salt or a eutectic, a composition, a preparation method and medical uses thereof, wherein the general formula (I) is defined in the specification, and each substituent is defined in the specification.

NO-RELEASING NONOATE (NITROGEN-BOUND) SULFONAMIDE-LINKED-COXIB ANTI-CANCER AGENTS

The present invention provides NO-releasing NONOate(nitrogen bound)sulfonamide- linked-coxib anti-cancer agents, having the structure of Formula (I): wherein R1, X, L, R2, R3, R4, and Z are as defined in the detailed description; pharmaceutical compositions comprising at least one compound of Formula (I); and methods useful for healing wounds, preventing and treating cancer, or treating actinic keratosis, cystic fibrosis or acne, using a compound of Formula (I).

COMPOUNDS AND THERAPEUTIC USES THEREOF

The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders.

PYRIMIDINE AMIDE COMPOUNDS

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, asthma and COPD.

PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE

The invention relates to prodrugs of fused heterocyclic inhibitors of D-amino oxidase (DAAO) and methods of treating diseases and conditions, wherein modulation of D-amino acid oxidase activity, D-serine levels, D-serine oxidative products and NMDA receptor activity in the nervous system of a mammalian subject is effective.

Enhancing the intestinal membrane permeability of zanamivir: A carrier mediated prodrug approach

The purpose of this study was to improve the membrane permeability and oral absorption of the poorly permeable anti-influenza agent, zanamivir. The poor oral bioavailability is attributed to the high polarity (cLogP ～ -5) resulting from the polar and zwitterionic nature of zanamivir. In order to improve the permeability of zanamivir, prodrugs with amino acids were developed to target the intestinal membrane transporter, hPepT1. Several acyloxy ester prodrugs of zanamivir conjugated with amino acids were synthesized and characterized. The prodrugs were evaluated for their chemical stability in buffers at various pHs and for their transport and tissue activation by enzymes. The acyloxy ester prodrugs of zanamivir were shown to competitively inhibit [3H]Gly-Sar uptake in Caco-2 cells (IC50: 1.19 ± 0.33 mM for l-valyl prodrug of zanamivir). The l-valyl prodrug of zanamivir exhibited ～3-fold higher uptake in transfected HeLa/hPepT1 cells compared to wild type HeLa cells, suggesting, at least in part, carrier mediated transport by the hPepT1 transporter. Further, enhanced transcellular permeability of prodrugs across Caco-2 monolayer compared to the parent drug (Papp = 2.24 × 10-6 ± 1.33 × 10-7 cm/s for l-valyl prodrug of zanamivir), with only parent zanamivir appearing in the receiver compartment, indicates that the prodrugs exhibited both enhanced transport and activation in intestinal mucosal cells. Most significantly, several of these prodrugs exhibited high intestinal jejunal membrane permeability, similar to metoprolol, in the in situ rat intestinal perfusion system, a system highly correlated with human jejunal permeability. In summary, this mechanistic targeted prodrug strategy, to enhance oral absorption via intestinal membrane carriers such as hPepT1, followed by activation to parent drug (active pharmaceutical ingredient or API) in the mucosal cell, significantly improves the intestinal epithelial cell permeability of zanamivir and has the potential to provide the high oral bioavailability necessary for oral zanamivir therapy.

Novel Phosphinic Acid-Containing Thyromimetics

The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.

Novel multifunctional acyloxyalkyl ester prodrugs of 5-aminolevulinic acid display improved anticancer activity independent and dependent on photoactivation

Multifunctional acyloxyalkyl ester prodrugs of 5-aminolevulinic acid in cancer cell lines inhibited the proteasome and induced apoptosis and heme synthesis. The most potent prodrug was butyryloxymethyl 5-amino-4-oxopentanoate (1a). The metabolically released formaldehyde from the prodrugs was the dominant factor affecting cell viability by a ROS-dependent mechanism and was responsible for rapid phosphorylation of H2AX, suppression of the cell survival protein c-myc, and transient elevation in the expression of p21. 1a, which differs from 2a by releasing butyric instead of pivalic acid, was a more potent inducer of heme and acetylated H4 expression and induced apoptosis through activation of caspase 9. 1a and 1b specifically increased the level of the photosensitizer protoporphyrin 9, leading to enhancement of cell death by photodynamic therapy (PDT). The advantage of these multifunctional prodrugs over 5-ALA is their greater potency in the non-PDT mechanism of cancer cell killing and their ability to also augment PDT.

BENZIMIDAZOLE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF

The present invention relates to a compound represented by the following formula wherein each symbol is as defined in the specification, or a salt thereof, which has superior stability to acid and which is a prodrug of 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole. This compound (1) shows a superior anti-ulcer activity, a gastric acid secretion-suppressive action, a mucosa-protecting action, an anti-Helicobacter pylori action and the like in living organisms, (2) shows low toxicity, (3) shows superior stability to acid (which obviates the need to formulate an enteric-coated preparation, thereby lowering the cost, and reduces the size of preparation to facilitate swallowing for patients having difficulty in swallowing), (4) shows faster absorption than enteric-coated preparations (rapid expression of gastric acid secretion-suppressive action), and (5) is sustainable.

Prodrugs of CL316243: A selective β3-adrenergic receptor agonist for treating obesity and diabetes

CL316243 is a highly selective and potent β3-adrenergic receptor agonist, and has been shown in rodent models to be an effective agent for treating obesity and Type II diabetes. To improve the oral absorption and pharmacokinetic profiles of CL316243, a number of prodrugs have been synthesized and evaluated. Several ester-type prodrugs show significant improvements in oral bioavailability in both rodent and primate models.